Injury, Occupational Diseases, Poisoning
Conditions
Interventions
Nacetyl cysteine intravenous solution standard 21 hour NAC regimen
N acetyl cysteine intravenous solution 12 hour regimen
Sponsors
Self sponsor
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 12 years or older (male and female) presenting with acute paracetamol toxicity requiring N-acetylcysteine treatment as per national guidelines (e.g., TOXBASE criteria). This includes patients admitted within 8 hours of a single acute paracetamol overdose, or presenting with a staggered overdose or uncertain time of ingestion requiring NAC.
Exclusion criteria
Exclusion criteria: patients aged less than 12 years old 2- known hypersensitivity or contraindication to N-acetylcysteine 3-individuals with pre-existing severe liver disease (e.g., cirrhosis, chronic liver failure) or other chronic comorbidities that may confound liver function assessment (e.g., chronic kidney disease, severe cardiovascular disease, diabetes, chronic pulmonary disease).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the study will be the incidence of hepatotoxicity, defined as an Alanine Aminotransferase (ALT) level greater than 1000 U/L within 48-72 hours of admission. | — |
Secondary
| Measure | Time frame |
|---|---|
| -The secondary outcomes will include the incidence and severity of adverse drug reactions (ADRs) to NAC (e.g., anaphylactoid reactions, nausea, vomiting), the duration of hospital stay, the need for intensive care unit (ICU) admission or intubation, the mortality rate, changes in liver function tests (ALT, AST, Bilirubin) and INR over time, the total dose of vasopressors required (if applicable), and arterial blood pressure and arterial blood gas parameters. | — |
Countries
Egypt
Contacts
Public ContactHafsa salah
lecturer
Outcome results
None listed